Dr. Mayes has received speaking fees (less than $10,000) from Actelion and book royalties (less than $10,000) from Oxford University Press.
Does C-Reactive Protein Predict the Long-Term Progression of Interstitial Lung Disease and Survival in Patients With Early Systemic Sclerosis?
Article first published online: 26 JUL 2013
Copyright © 2013 by the American College of Rheumatology
Arthritis Care & Research
Volume 65, Issue 8, pages 1375–1380, August 2013
How to Cite
Liu, X., Mayes, M. D., Pedroza, C., Draeger, H. T., Gonzalez, E. B., Harper, B. E., Reveille, J. D. and Assassi, S. (2013), Does C-Reactive Protein Predict the Long-Term Progression of Interstitial Lung Disease and Survival in Patients With Early Systemic Sclerosis?. Arthritis Care Res, 65: 1375–1380. doi: 10.1002/acr.21968
- Issue published online: 26 JUL 2013
- Article first published online: 26 JUL 2013
- Accepted manuscript online: 11 FEB 2013 10:07AM EST
- Manuscript Accepted: 18 JAN 2013
- Manuscript Received: 22 SEP 2012
- NIH/National Institute for Arthritis and Musculoskeletal and Skin Diseases. Grant Numbers: P50-AR-054144, K23-AR-061436
- NIH/Institute of Allergy and Infectious Diseases. Grant Numbers: U01-AI-09090, U01-AI-09090
- NIH. Grant Number: T32-AR-052283
There are no identified clinical markers that reliably predict long-term progression of interstitial lung disease (ILD) in systemic sclerosis (SSc; scleroderma). Elevated C-reactive protein (CRP) levels have been reported in SSc patients. We examined the predictive significance of CRP level for long-term ILD progression in a large early SSc cohort.
First, the CRP levels were compared between baseline samples of 266 SSc patients enrolled in the Genetics Versus Environment in Scleroderma Outcome Study cohort and 97 unaffected matched controls. Subsequently, the correlation between CRP levels and concomitantly obtained markers of disease severity was assessed. Serially obtained % predicted forced vital capacity (FVC) was used to examine the long-term ILD progression. The predictive significance of CRP level was investigated by a joint analysis of longitudinal measurements (serial FVCs up to 13 years) and survival data. This approach allowed inclusion of all 1,016 FVC measurements and accounted for survival dependency.
We confirmed that baseline CRP levels were higher in SSc patients than controls. CRP levels were associated with absence of anticentromere antibodies and correlated with the concomitant severity of lung, skin, and joint involvement. More importantly, higher baseline CRP levels were associated with shorter survival (P < 0.001) and predicted the long-term decline in FVC independent of potential confounders (age at baseline, sex, ethnicity, disease type, current smoking, body mass index, topoisomerase status, and treatment with immunosuppressive agents) in the multivariable model (P = 0.006).
Baseline CRP levels are predictive of long-term ILD progression. CRP level might aid clinicians in identifying patients that require more intensive monitoring and treatment.